Echosens

Echosens

October 30, 2009 03:00 ET

Echosens Is a Major World Actor in Elastography

PARIS, FRANCE--(Marketwire - Oct. 30, 2009) - Last month, at the Institute of Electrical and Electronics Engineers (IEEE) Conference in Rome, Echosens presented a series of papers and posters on its research work, including Viscosity and Micro-Elastography. Some of its new applications will also be presented during the American Association for the Study of Liver Disease (AASLD) in Boston, from October 30 to November 3, 2009.

Echosens' Transient Elastography is the first to be implemented clinically using the Fibroscan® non-invasive evaluation tool for liver fibrosis. Thus, it is the only technique that can benefit, to this day, from a unique clinical history backed by over 250 independent publications and 300 communications on chronic liver disease. This technology differs from other Elastography techniques thanks to its high sensitivity and specificity but also its unmatched reproducibility corroborated by clinical data provided by 700 devices installed all over the world.

Since 2003, the unique Fibroscan VCTE™ Technology for Vibration Control Transient Elastography has continued to evolve, such that Echosens has developed different probes to examine patients presenting various morphologies ranging from the infant to the obese. This unique technique applied to the liver, as validated by the Haute Autorite de Sante in France , is now in the process of reimbursement, and its technological and clinical development continues on and is providing unique indications as in NASH (Non Alcoholic Steato-Hepatitis) or Cirrhosis complications.

Today, Echosens is diversifying its research developments around the VCTE™ Core Technology with applications such as the CAP(2) on the evaluation of Steatosis in liver diseases but also of "Micro-Elastography" (the ability to work on small volumes) that could soon be applied to other organs.

Echosens: Partner for diagnostic solutions in Hepatology

Founded in 2001, Echosens dedicates a significant part of its activity on research in order to develop new medical devices and open up new medical perspectives. The Company works in close cooperation with health professionals and patients' associations to facilitate patients' therapeutic follow up.

(2) POSTER 16 (# 998) Novel ultrasonic FibroScan®-based steatosis index for hepatic steatosis quantification in 618 HCV patients

Contact Information